UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 23, 2016
BEIGENE, LTD.
(Exact name of registrant as specified in its charter)
|
Cayman Islands
|
|
001-37686
|
|
98-1209416
|
c/o Mourant Ozannes Corporate Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of principal executive offices) (Zip Code)
+1 (345) 949 4123
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 23, 2016, the board of directors of BeiGene, Ltd. approved performance-based cash bonuses for the year ended December 31, 2015 for each of (i) John V. Oyler, Chief Executive Officer and Chairman, in the amount of $172,352, (ii) Howard Liang, Chief Financial Officer and Chief Strategy Officer, in the amount of $48,650 (pro rata bonus for the portion of the year employed), and (iii) RuiRong Yuan, Chief Medical Officer and President of Global Clinical Research and Development, in the amount of $26,267 (pro rata bonus for the portion of the year employed).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BEIGENE, LTD. |
|
|
|
|
|
|
|
|
|
|
Date: March 29, 2016 |
By: |
/s/ Howard Liang |
|
|
Name: |
Howard Liang |
|
|
Title: |
Chief Financial Officer and Chief Strategy Officer |